Abemaciclib with Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update
ASCO Guidelines
00:00
Exploring the Efficacy of Adjuvant CDK4-6 Inhibitors in Early-Stage Breast Cancer
This chapter delves into the complexities of adjuvant therapies, specifically CDK4-6 inhibitors like abemaciclib, in early-stage breast cancer treatment. It highlights the unexpected advantages of abemaciclib and underscores the necessity for further research into patient outcomes and treatment tolerability.
Play episode from 06:51
Transcript
